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BACKGROUND: Upper abdominal exenteration (resec-
tion of the liver, stomach, spleen, pancreaticoduodenal 
complex, and part of the colon) for the treatment 
of otherwise unresectable tumors is one of the more 
radical operations in oncology. This study was done 
to analyze retrospectively a five-year experience with 
exenteration in 57 patients treated with variations of 
resectional and transplant reconstructive techniques. 
STUDY DESIGN: Sixty-one transplantations were per-
formed upon 57 patients. Three different organ re-
placement techniques were used: liver-pancreas-duo-
denum en bloc (original procedure), liver only 
(modified procedure), and liver plus pancreatic islets. 
The diagnoses were cholangiocarcinoma (20 patients), 
hepatocellular carcinoma (12 patients), endocrine neo-
plasms (14 patients), sarcoma (six patients), and ade-
nocarcinoma of the pancreas (two patients), colon 
(two patients), or gallbladder (one patient). Analyses 
of survival and tumor recurrence were stratified by 
procedure variations, type and extent of tumor, and 
immunosuppressive regimen. 
RESULTS: The three month and one, two, three, and 
five year actuarial patient survival rates were 82, 56, 
38, 33, and 30 percent, respectively. Eighteen (31.5 
percent) of the 57 patients are alive after 425 15 
(standard deviation) months (range of 17 to 61 
months) and 12 patients are tumor free. The actuarial 
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survival rates stratified by transplantation procedure, 
immunosuppression, and tumor diagnosis and extent 
showed no statistically significant differences beyond 
the three different transplantation groups. Endocrine 
tumors had a better three-year survival rate (64 per-
cent) than sarcoma (44 percent), hepatocellular car-
cinoma (25 percent), cholangiocarcinoma (20 percent), 
and the other adenocarcinomas (20 percent). Twenty-
three patients (40 percent) died as a result of tumor 
recurrence. Patients with combined factors of no 
lymph node involvement, absence of vascular invasion, 
and metastases to the liver ouly (11 patients) had 
the lowest incidence of recurrence (27 compared to 
73.5 percent, p=0.006). 
CONCLUSIONS: Patients with unresectable endocrine 
neoplasms, fibrolamellar hepatocellular carcinoma, 
and selected cholangiocarcinoma conf'med to the liver 
can benefit from this radical operative approach. Pa-
tients with sarcoma can achieve long survival periods 
but have a high recurrence rate. J. Am. Coil. Surg., 
1995, 180: 1-9. 
CLUSTER EXENTERATION has been used to treat pa-
tients with otherwise nonresectable malignancies 
of the upper abdominal tract. In most cases, the 
organs excised with this procedure were the liver, 
pancreas, spleen, stomach, duodenum, and vari-
able amounts of the colon. Lately, two more con-
servative procedures have been used in some 
selected cases, with preservation of part of the 
stomach, or preservation of the body and the 
tail of the pancreas, or preservation of both 
(Whipple procedure), combined with a total 
2 Journal of the American College of Surgeons . January 1995 . Volume 180 
TABLE I.-CASE r-L\TERIAL 
Disease categories 
ChnlangiocarcinOIll<l ..... . 
Endocrine . . . . .... . 
Hepatocellular Gtrcinoma ........... . 
Sarcoma .................. . 
Others ........ . 
Type of cluster transplan t 
Original ..... 
Modified . . . .. . ..... 
Islets and liver . . . . . . . . . . . . . . . . . 
IInmunosuppressi(ln 
Cyclosporine . . . . . . . . . . . . . . . . . . . . 
FK C,06 ..... . 











There were 57 palit'nts (33 males alld ~4 females) in the studv with ;\ 
mean age of 40±11 years (range of eight to 59 rars). . 
No .• Number. 
hepatectomy. Three different organ replacement 
techniques have been used, all including the liver 
(1-3). 
This is one of the more radical operations in 
oncology, for which reason it has been contro-
versial. Ethics questions have concerned the sur-
vival of these patients, the possibility of control-
ling such advanced tumors, and the influence 
of original tumor diagnosis and extent on out-
come. We have examined these and other issues 
in 57 consecutive patients who underwent exen-
teration one to almost five years ago. 
METHODS 
Case material. The '57 patients were treated be-
tween July 22, 1988 and June 4, 1992 and had 
follow-up evaluation to the end of 1993. Their 
ages ranged from eight to 59 years, with an equal 
distribution between genders. Before transplan-
tation, 37 patients had normal liver function tests 
(LFT). Twenty patients had minor to moderate 
elevation of LFT but no hepatic failure or severe 
portal hypertension. Seventeen of the patients 
and two other patients with othenvise good he-
patic function had jaundice at the time of the 
operation, with a mean total bilirubin level of 
8.5 ± 4.3 (standard deviation) mg/ dL. None of 
the patients were in renal failure before the trans-
plant. One patient had diabetes mellitus. 
Conventional operative treatment (including 
exploratory laparotomies) had been attempted 
in 30 patients; 19 patients had been treated with 
chemotherapy or radiation, or both. One patient 
previously treated for hepatocellular carcinoma 
(HCC) with hepatic transplantation underwent 
the cluster procedure when the malignancy re-
curred in the hepatic allograft. All of the patients 
were considered incurable hy conven tional medi-
cal treatment or operation at the time of the 
cluster operation. 
Tumor pathology. There were 20 patients with 
cholangiocarcinoma (12 extrahepatic and eight 
intrahepatic) and 12 with HCC (Table I). Of 
special interest were three patients with fibro-
lamellar HCC, all with metastases to lymph nodes; 
two of the three had vascular invasion. The other 
patients had either endocrine neoplasms of pan-
creatic, enteric, or gastric origin (14 cases), gas-
trointestinal sarcoma (six cases), adenocarcinoma 
of the pancreas (two cases), adenocarcinoma of 
the colon (two cases), or adenocarcinoma of the 
gallbladder (one case). There were extensive he-
patic metastases in all but three of the 57 cases. 
Lymph nodes draining the liver, or other por-
tions of the removed specimens, contained tumor 
in 31 of the 57 cases. Metastases to other whole 
organs (in addition to the hepatic involvement) 
were present in 18 patients. Macroscopic vascular 
invasion was found in 33 of the livers. Onlv 11 
of the 57 patients had a triad of favorable findings 
consisting of negative nodes, absence of vascular 
invasion, and confinement of metastases to the 
liver. In two of the 11 patients, the hepatic pa-
renchyma was free of metastases from a pancre-
atic endocrine tumor in one case and an ade-
nocarcinoma of the pancreas in the other. Tn 
these two exceptions, extensive invasion of the 
extrahepatic biliary tree necessitated total hepatec-
tomy. 
Transplantation procedures. The 57 patients un-
derwent 61 transplantations. The principles (1, 
4) as well as details (l, 2, 5) of both the donor 
and recipient operations have been described 
elsewhere. The most common variation of the 
complete exenteration was presen'ation of part 
of the stomach in 12 patients (Fig. la, b, and 
c), of whom. three also retained the bodv and 
the tail of the pancreas, as with the whipple 
operation (Fig. 1 b). All but one of the 57 primary 
cadaveric donors were ABO blood group identical 
with the recipients, the only exception being an 
o to B combination for a patient too ill to wait 
for a matched graft. Similar degrees of urgency 
prompted the acceptance of nonidentical donor-
recipient pairing (0 to A and 0 to B) for two 
of the four retransplantations. Human leukocyte 
antigen matching was random and uniformly 
poor. The lymphocytotoxic cross-match was posi-
tive in five of the 61 transplantations. 
The transplantation technique provided a basis 
for stratification of results: 
l. Original cluster operation (l, 6). Twen tv-
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Original Cluster 
a 
FIG. 1. a, Original cluster procedure with transplantation 
of liver-pancreas-duodenum en bloc. In two cases, part of 
the stomach was preserved and the transplanted duodenum 
was placed in continuity with the stomach and jejunum 
of the patient (inset). b, Modified cluster procedure with 
transplantation of the liver only. In eight patients, one-third 
or more of the recipient stomach was preserved (inset, 
right), including three patients in whom the body and the 
tail of the pancreas also were retained (inset, left). c, Islet 
cluster procedure with transplantation of the liver and pan-
creatic islets injected into the portal vein of the transplanted 
liver. In two patients, part of the recipient stomach was 
preserved (inset). 
three composite grafts were transplanted to 21 
patients. These consisted of the liver, pancreas, 
duodenum, and variable amounts of proximal 
jejunum (Fig. la). Two of these grafts were used 
for retransplantation four days after the primary 
procedure. 
2. Modified cluster operation (2, 7). In 25 pa-
tients, the excised specimen was replaced with 
the liver only (n=27, including two retransplan-
tations). The two retransplantations were one and 
73 days, respectively, after the primary operation. 
In eight of the 25 cases, one-third or more of 
the recipient stomach was preserved (Fig. Ib), 
including three patients in whom the body and 





recipients whose entire pancreas was excised be-
came diabetic immediately. 
3. Islet cluster. These 11 patients had islets 
prepared from the liver donor pancreas injected 
into the portal vein of the transplanted liver be-
fore the abdominal incision was closed (Fig. Ie). 
The details of islet preparation and the deter-
mination of islet viability and doses are given 
elsewhere (3). 
Immunosuppression. Prophylaxis against graft-ver-
sus-host disease (GVHD) was attempted with do-
nor pretreatment in eight of the first ten cases 
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FIG_ 2_ The overall actuarial patient survival rale curve. 
by infusion of 10 to 20 mg of OKT3 during or 
preceding organ procurement. The first 32 pa-
tients were treated with cyclosporine (eyA) and 
prednisone immunosuppression to which a pro-
phylactic 10-to-l4-day course of OKT3 was added 
perioperatively in the first 15 patients. Azathio-
prine was begun when and if the white blood 
count exceeded 5,000 mm3 . These regimens have 
been described elsewhere (1). Several of these 
recipients were later changed to FK 506. FK 506 
combined with prednisone was used in the last 
25 patients, adjusting the dose on clinical grounds 
and by monitoring FK 506 plasma levels. 
Statistical analysis. Survival curves were gener-
ated using the Kaplan-Meier (product limit) 
method and were compared using the general-
ized Wilcoxon's (Breslow) test. The chi-square 
test of association was used to compare propor-
tions. A p value of less than 0.05 was considered 
statistically significant. 
RESULTS 
Overall patient survival. All patients survived the 
operation, although four required retransplanta-
tion one, four, four, and 73 days later, respec-
tively. At three months, the patient survival rate 
was 82 percent. The one, two, three, and five 
year actuarial patient survival rate was 56, 38, 
33, and 30 percent, respectively (Fig. 2). Eighteen 
(31.5 percent) of the 57 patients are alive after 
42±15 months (range of 17 to 61 months). Only 
two patients have less than two years of follow-up 
evaluation. Six of the 18 survivors have recurrent 
tUlll0r. 
Stratified patient survival. By transplan tation pro-
cedure.-The actuarial survival rates for the three 
cohorts of patients that underwent original, modi-
fied, or islet cluster transplantation are illustrated 
in Figure 3. The actuarial one, two, and three 
year survival rates were 48, 38, and 33 percent 
in the original cluster group; 60, 39, and 31 
percent in the modified cluster group; and 63, 
34, and 34 percent in the islet cluster group. 
The differences were not significant. 
By immunosuppression.-There is a trend of 
better survival in the FK 506 cohort (Fig. 4). 
However, the cyclosporine and FK 506 cohorts 
were not statistically comparable because they 
were consecutive and there were differences in 
neoplastic disease and type of transplantation pro-
cedure. 
By tumor histology.-The actuarial survival 
rates of the five groups were not significantly 
different (Fig. 5). However, patients with endo-
crine and sarcoma neoplasms had a better survival 
rate when compared with the others. At three 
years, the survival rate was 64 percent for patients 
with endocrine tumors, 44 percent for those with 
sarcoma, and 20 to 25 percent in the other three 
tumor groups. 
By tumor extent.-Patients with metastases to 
local and regional lymph nodes had almost the 
same one, two, and three year survival rates (52, 
38, and 33 percent, respectively) as those with 
negative nodes (62, 37, and 33 percent, respec-
tively). The survival rate for one, two, and three 
years was better in patients without tumor vascular 
invasion than with this finding, but the differ-
ences were not significant (data not shown). Pa-
tients with metastases in other whole organs in 
addition to the liver had survival rates at one, 
two, and three years of 50, 38, and 20 percent, 
respectively, while those with tumor confined to 
the liver had survival rates at these times of 59, 
38, and 38 percent, respectively (data not shown). 
The survival rates were 64, 45, and 45 percent 
at one, two, and three years, respectively, for 
the 11 patients who had all three of the presumed 
favorable conditions of no lymph node metasta-
ses, absence of vascular invasion, and confine-
ment of metastases to the liver. For the other 
46 patients, the survival rates at one, two, and 
three years were 54, 36, and 29 percent, respec-
tively. These differences were not statistically sig-
nificant because of the low number of patients 
in the first group (data not shown). 
Analysis of deaths. Nontumor related.-Ten pa-
tients died perioperatively or during the first 
three months postoperatively, eight as a result 
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FIG. 3 FIG. 4 
Fa; 3. The actuarial patient survival rate stratified by transplantation procedure: original cluster 
(liver-pancreas-duodenum), modified cluster (liver only), and liver plus pancreatic islets. 
FIG. 4. The actuarial patient survival rate stratified by immunosuppression with cyclosporine 
or FK 506. 
tions. The two other early deaths were a result 
of intra-abdominal hemorrhage and multiorgan 
lymphoproliferative disease. Of the eight patients 
who were septic, one had recurrence at the time 
of death. This recipient had tumor in the resected 
margin of the upper vena cava of the multivisceral 
specimen. 
year. An example was a patient with a duct cell 
carcinoma who died from rupture of a mycotic 
aneurysm of the celiac Carrel patch after 345 
days. Hepatic artery thrombosis in another patient 
resulted in death after an unsuccessful retrans-
plantation. In the second postoperative year, a 
woman with renal failure, who was noncompliant, 
committed suicide at 19 months after ceasing 
medications and refusing further treatment, in-
cluding dialysis. All but one of the six patients 
Five more deaths occurred as a result of delayed 
technical or other nontumor complications and 
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SARCOMA OTHERS HCC CHOLANGIOCA ENDOCRINE 
FIG. 6. Incidence of recurrence within each tumor diag-
nosis group. Patients who died within the first three months 
from technical or nontumor complications (ten cases), as 
well as those in whom gross tumor remained (two cases) 
were excluded from this analysis. HCC, Hepatocellular car-
cinoma, and cholangioca, cholangiocarcinoma. 
who died after the first three months were tumor 
free at the time of death. In the one exception, 
micrometastases of cholangiocarcinoma were an 
incidental finding at autopsy, 
The number of patients who died as a result 
of causes not related to tumor recurrence was 
16 (28 percent). The incidence of the nontumor-
related mortality in the different transplantation 
procedure groups was 33 percent in the original 
cluster, 24 percent in the modified cluster, and 
27 percent in the islet cluster groups. The dif-
ferences were not significant statistically. The special 
group of 11 patients with only hepatic metastases 
had a 36 percent incidence of nontumor-related 
mortality, compared with 26 percent for the other 
population. The groups did not differ signifi-
cantly. 
No differences were seen between the CyA and 
the FK 506 groups, but a trend of more frequent 
fatal sepsis was present in the CyA group (25 
versus 16 percent). Lymphoproliferative disease 
accounted for the death of a patient who was 
FK 506 immunosuppressed. 
Tumor related.-Twenty-three patients (40 per-
cent) died as a result of tumor recurrence after 
a mean survival period of 515 ± 430 days (range 
of 91 to 1,948 days). In the special group of 
11 patients with hepatic metastases only, the in-
cidence of death from recurrence was 27 percent, 
while in the other 46 patients, the incidence 
was 44 percent. 
There was only one example (7 percent) of 
a lethal recurrence of an endocrine tumor (car-
cinoid of the pancreas) causing death after 289 
days. The incidence and median time of tumor-
related mortality was 45 percent for cholangio-
carcinoma (562 days), 50 percent for HCC (327 
days), 60 percent for adenocarcinoma of the pan-
creas, colon, or gallbladder (259 days), and 66.6 
percent for sarcoma (938 days). The latest tu-
mor-related death was a 31-year-old woman whose 
diagnosis was sarcoma of the duodenum with 
massive hepatic metastases. Mter four years, me-
tastases to the brain were noted on a computer 
tomographic scan and the patient died as a result 
of disseminated tumor recurrence after five years 
and four months. 
The different transplantation techniques had 
no influence on the incidence of tumor-related 
mortality, which was 43, 40, and 36 percent in 
the original, modified, and islet cluster procedure 
groups, respectively. The incidence of death from 
recurrence was higher in the CyA group (50 
percent) than in the FK 506 group (28 percent), 
but this difference was not significant. 
Analysis oj recurrence. To better define the real 
incidence of and the influence of the different 
procedures on recurrence, the ten patients who 
died within the first three months as a result 
of technical or non tumor complications were ex-
cluded, as well as two others who died later in 
whom gross tumor was left at the resection mar-
gin. The two patients who were excluded who 
died as a result of recurrence after three months 
(197 and 304 days) were omitted from the analysis 
because there was roentgenographic and other 
evidence in both of extension of the cholangio-
carcinomas beyond the surgical boundaries at 
the time of operation. 
The remaining 45 patients who had at least 
three months of follow-up evaluation had a 62 
percent incidence of tumor recurrence. Sarcoma 
was the highest (83 percent), followed by the 
mixed group of adenocarcinoma of the pancreas, 
colon, and gallbladder (75 percent), HCC (70 
percent), cholangiocarcinoma (57 percent), and 
endocrine tumor (45.5 percent) (Fig. 6). The 
differences within these five groups were not sta-
tistically significant. 
All of the 11 patients with no lymph node 
metastases, no vascular invasion, and absence of 
metastases to whole organs other than the liver 
were among the culled 45 patients. Their recur-
rence rate was 27 percent compared with 73.5 
percent in the remaining 34 patients (p=0.006). 
Analysis of the surviving patients. Of the 18 pa-
tients alive, 12 are tumor free after 42 ± 15 months 
(range of 17 to 61 months). Interestingly, two 
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of the three patients with fibrolamellar HCC are 
well at 28 and 47 months, respectively. Of these 
two patients, the one surviving the longest period, 
a 21-year-old woman, was operated upon and 
treated with adjuvant chemotherapy for a right 
mandibular recurrence two years after the exen-
teration. Although she is clinically well at 47 
months, a recent cervical lymph node biopsy re-
vealed recurrent tumor. The other patient with 
the fibrolamellar variant has no evidence of re-
currence. The third living patient of the HCC 
group is a 52-year-old physician who presented 
preoperatively with two HCC nodules in the cir-
rhotic liver, one in the right lobe and the other 
in the caudate lobe, with portal vein invasion 
and direct invasion of the contiguous pancreas. 
Mter three courses of pretransplant intra-arterial 
local and regional chemotherapy, modified clus-
ter exenteration was performed with preservation 
of part of the stomach and of the distal portion 
of the pancreas. Mter 29 months, the patient 
has no evidence of recurrence. 
Three patients with cholangiocarcinoma who 
are alive without recurrence at 52, 54, and 59 
months, respectively, belonged to the special group 
of 11 patients with hepatic metastases only. The 
primary lesion in these three patients was in the 
extrahepatic ducts, which was thought to preclude 
hepatic transplantation alone. Another patient 
with adenocarcinoma of the pancreas has no evi-
dence of recurrence at 44 months. 
One of the two patients with sarcoma is alive 
at 19 months with recurrence, and the other 
patient is tumor free at 49 months. Three patients 
are alive at 33, 50, and 56 months, respectively, 
with recurrent endocrine tumor. A fourth patient 
with endocrine tumor diagnosis is alive at 18 
months, but with a biopsy-proved primary ade-
nocarcinoma of the lung, which was diagnosed 
after eight months. Five patients with pretrans-
plant diagnosis of endocrine tumor are alive with-
out evidence of disease at 17, 27, 32, 54, and 
61 months, respectively. Of these, the patient 
who is alive at 32 months presented a difficult 
technical problem because the tumor (a gastri-
noma) was found inside the upper vena cava, 
invading the right atrium. During the exentera-
tion, the diaphragm was opened and the entire 
upper vena cava and part of the wall of the 
right atrium were excised and replaced with both 
donor structures (Fig. 7). This patient, who also 
had an infusion of donor pancreatic islets, now 
has a normal life. 
Nutritional status. The nutritional complications 
FIG. 7. Transplantation technique in a patient with gas-
trinoma invading the upper vena cava and the right atrium. 
The entire upper vena cava and part of the wall of the 
right atrium were excised and replaced with both donor 
structures. This patient, whose entire pancreas was removed, 
had donor pancreatic islets infused into the portal vein 
and is insulin free after four years. 
of the cluster operations have been previously 
reported (1, 7). Malabsorption, diarrhea, and 
weight loss occurred in all patients, but the ex-
planation was frequently difficult to sort out be-
cause of the frequent technical complications in 
early stages and tumor recurrence later. Conse-
quently, we separately analyzed the 12 patients 
who are alive without evidence of tumor. 
During the first three months, these patients 
lost 15 ± 8 percent of their preoperative body 
weight. Later, they maintained this level with only 
an additional 5 percent loss during the first two 
years. At three years or at the latest follow-up 
evaluation (42 ± 15 months), or both, the weight 
remained stable. Two patients still require occa-
sional home parenteral nutrition support at night 
to maintain a regular weight. In the only surviving 
patient with nonfibrolamellar HCC, the current 
weight after 29 months is higher than before 
operation. 
In the group of 12 patients, there were seven 
patients with retention of a significant gastric 
remnant and five without this advantage (Fig. 
8). Patients with a gastric remnant had minor 
weight loss that was limited to the first three 
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F1G. 8. The mean percent of weight loss in the surviving 
patients who are tumor free who had part of the stomach 
preserved (GP=7 cases) and those in whom total gastrectomy 
was performed (NGP=5 cases). Gp, Gastric preservation, 
and NGp, nongastric preservation. 
months compared to the other cohort. However, 
the weight of those with total gastrectomy sta-
bilized after one vear. 
/ 
Four of the 12 patients received pancreatic islet 
allografts in addition to the liver (3) after com-
plete recipient pancreas removal. Two patients 
are insulin free at 44 and 47 months, respectively, 
while the other two require daily insulin injec-
tions. 
DISCUSSION 
One purpose of this follow-up study was to 
define the patient populations that might be 
helped by the radical cluster operations, consid-
ering histopathologic criteria and degree of me-
tastatic extension. Grouping all tumor types to-
gether, the results were favorably influenced by 
the triad of negative lymph nodes, involvement 
of no more than one whole organ, and absence 
of vascular invasion by tumor. The greatest bene-
fit was in patients with endocrine tumors, and 
the least was in those with adenocarcinoma of 
colon, pancreas, or gallbladder. Patients with sar-
coma survived for long periods, although they 
eventually had a high recurrence rate. Patients 
with cholangiocarcinoma had no significant bene-
fit from this procedure unless the primary tumor 
was confined to the liver and bile ducts. 
The prognosis was poor for patients with HCC, 
but as suspected from previous investigations (8), 
the fibrolamellar variant may be an exception. 
McMaster and co-workers (9) have argued that 
there is no legitimate place for the cluster pro-
cedure in the treatment of this disease, believing 
that conventionally unresectable hepatoma 
should either be treated by hepatic transplanta-
tion alone or not at all. Our experience, par-
ticularly with the fibrolamellar variant, does not 
support this position, although it has verified 
the poor outlook with advanced disease. All of 
the patients in our study with the diagnosis of 
HCC had tumor beyond the confines of an ex-
tended total hepatectomy, such as that described 
by McMaster and associates (9), including 30 per-
cent who had gross metastases in other whole 
organs. Two of three patients in our study with 
fibrolamellar HCC benefitted from treatment, com-
pared with only one in nine with the more com-
mon HCC in which the presence of multiple 
organ involvement or metastases in any of the 
lymph nodes was an ominous prognostic sign. 
Aside from survival, the nutritional morbidity 
caused by cluster operation was an observation 
end point. This seemed to be related to a balance 
between the extent of extirpation and the degree 
of organ replacement. The loss of the entire 
stomach was disabling, whereas weight loss and 
diarrhea were reduced in patients with a signifi-
cant gastric remnant. However, there may be no 
alternative to total gastrectomy if gross tumor is 
to be removed, and in such cases, variations of 
the multivisceral operation in which the hollow 
gastrointestinal organs are transplanted in con-
tinuity with the liver, may be an option. These 
so-called multivisceral operations, including the 
transplantation of the entire intra-abdominal gas-
trointestinal tract, have permitted restoration of 
a good quality of life for as many as three years 
in most patients with non-neoplastic disease (10-
12). 
Despite the high morbidity and mortality rates 
in these otherwise incurable patients, it is ap-
propriate to consider that nearly one of every 
three patients who entered the series is alive or 
expected to be alive at five years. Most of the 
surviving patients are functional in society (some 
completely normally), although two of them re-
quire overnight parenteral feedings to maintain 
their weight. Whether or not the benefit is judged 
to be sufficient to warrant further trials may be-
come moot because of the organ shortage that 
began during the case accrual of this study and 
evolved to crisis proportions by its conclusion. 
Few would debate the propriety of heroic efforts 
at carcinoma therapy resulting in a significant 
survival rate if there were an unlimited organ 
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supply. However, with the logic that organs can 
be more efficiently invested to patients without 
carcinoma, it may be that the cluster or mul-
tivisceral operations will have to wait the devel-
opment of xenotransplantation for a full evalu-
ation. 
Apart from the question of their practical clini-
cal application, the cluster procedures have con-
tributed lessons in biology and transplantation 
immunology. In supporting animal research, it 
was discovered by Murase and colleagues (13), 
and was confirmed by Iwaki and associates (14) 
in humans, that partial or complete multivisceral 
grafts became hematolymphopoietic chimeras 
within a short time after their transplantation 
with donor specific retention of the epithelial 
components, while the leukocyte constituency is 
replaced with a recipient population. This im-
portant discovery resulted directly in a realization 
that the interstitial donor white cells departing 
the grafts migrated ubiquitously in the recipient 
and survived, creating the systemic microchimer-
ism that we postulate to be the basis for accep-
tance of all kinds of grafts (15). 
Furthermore, the elucidation of this bidirec-
tional traffic has clarified much of the mystery 
about the feared complication of GVHD, includ-
ing the reason for its lack of appearance after 
the transplantation of lymphoid-rich organs, such 
as those in the composite cluster grafts (16). 
This paradigm of transplantation immunology has 
contained a warning (4, 16) against not only 
host preconditioning with immunosuppression, 
but equally against the kind of graft precondi-
tioning with lymphoid depletion that was at-
tempted with OKT3 in the first eight patients 
in our study. We have ascribed the high rate of 
lymphoproliferative tumors (B-cell lymphomas) 
in the early attempts at multivisceral transplan-
tation (17, 18) to the lymphoid depletion pro-
cedures (16). Fortunately, there was only one 
example of this complication in the 57 cases of 
the present series. Reversible GVHD was seen 
in only two patients, as noted elsewhere (16). 
It is also noteworthy that two of the 11 patients 
who had replacement of the liver combined with 
free pancreatic islet allografts remain alive in an 
insulin-free state after 44 and 47 months. Because 
these were the first patients in the world to Ull-
dergo successful pancreatic islet transplantation 
(3), they established the feasibility of this pro-
cedure after total pancreatectomy using a single 
donor source, and stimulated other successful 
trials elsewhere in patients with type I diabetes 
mellitus. 
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